Company Analysis Clarity Pharmaceuticals Ltd
1. Summary
Advantages
- The stock's return over the last year (109.69%) is higher than the sector average (-34.04%).
Disadvantages
- Price (5.55 $) is higher than fair price (2.13 $)
- Dividends (0%) are below the sector average (1.76%).
- The company's current efficiency (ROE=-33.85%) is lower than the sector average (ROE=13.19%)
Similar companies
2. Share price and performance
2.1. Share price
2.2. News
2.3. Market efficiency
| Clarity Pharmaceuticals Ltd | Healthcare | Index | |
|---|---|---|---|
| 7 days | -8% | 4.6% | 0.6% |
| 90 days | -54.3% | -37.6% | 1% |
| 1 year | 109.7% | -34% | 20.7% |
CLRPF vs Sector: Clarity Pharmaceuticals Ltd has outperformed the "Healthcare" sector by 143.73% over the past year.
CLRPF vs Market: Clarity Pharmaceuticals Ltd has outperformed the market by 88.99% over the past year.
Stable price: CLRPF is not significantly more volatile than the rest of the market on "OTC" over the last 3 months, with typical variations of +/- 5% per week.
Long period: CLRPF with weekly volatility of 2.11% over the past year.
3. Summary of the report
4. Fundamental Analysis
4.1. Stock price and price forecast
Above fair price: The current price (5.55 $) is higher than the fair price (2.13 $).
Price is higher than fair: The current price (5.55 $) is 61.6% higher than the fair price.
4.2. P/E
P/E vs Sector: The company's P/E (0) is lower than that of the sector as a whole (31.48).
P/E vs Market: The company's P/E (0) is lower than that of the market as a whole (46.91).
4.3. P/BV
P/BV vs Sector: The company's P/BV (10.16) is higher than that of the sector as a whole (3.36).
P/BV vs Market: The company's P/BV (10.16) is higher than that of the market as a whole (-8.98).
4.3.1 P/BV Similar companies
4.4. P/S
P/S vs Sector: The company's P/S indicator (0) is lower than that of the sector as a whole (3.24).
P/S vs Market: The company's P/S indicator (0) is lower than that of the market as a whole (4.88).
4.5. EV/Ebitda
EV/Ebitda vs Sector: The company's EV/Ebitda (0) is lower than that of the sector as a whole (9.95).
EV/Ebitda vs Market: The company's EV/Ebitda (0) is lower than that of the market as a whole (25.28).
5. Profitability
5.1. Profitability and revenue
5.2. Earnings per share - EPS
5.3. Past profitability Net Income
Yield Trend: Rising and has grown by 101.73% over the last 5 years.
Earnings Slowdown: The last year's return (0%) is below the 5-year average return (101.73%).
Profitability vs Sector: The return for the last year (0%) exceeds the return for the sector (-52.93%).
5.4. ROE
ROE vs Sector: The company's ROE (-33.85%) is lower than that of the sector as a whole (13.19%).
ROE vs Market: The company's ROE (-33.85%) is lower than that of the market as a whole (-8.22%).
5.5. ROA
ROA vs Sector: The company's ROA (-31.35%) is lower than that of the sector as a whole (6.14%).
ROA vs Market: The company's ROA (-31.35%) is lower than that of the market as a whole (4.85%).
5.6. ROIC
ROIC vs Sector: The company's ROIC (0%) is lower than that of the sector as a whole (15.56%).
ROIC vs Market: The company's ROIC (0%) is lower than that of the market as a whole (11.03%).
7. Dividends
7.1. Dividend yield vs Market
Low yield: The dividend yield of the company 0% is below the average for the sector '1.76%.
7.2. Stability and increase in payments
Unstable dividends: The company's dividend yield 0% has not been consistently paid over the past 7 years, DSI=0.
Weak dividend growth: The company's dividend yield 0% has been growing weakly or stagnant over the past 5 years. Growth over only 0 years.
7.3. Payout percentage
Dividend Coverage: Current payments from income (0%) are at an uncomfortable level.
Pay for your subscription
More functionality and data for company and portfolio analysis is available by subscription
